Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2499${count})

  • Research Grant, 2013
    Advancement of Quantitative Disease Progression Modeling of Parkinson’s Disease

    Objective/Rationale:             
    In clinical trials, the progression of Parkinson’s disease (PD) is primarily measured by the change in total Unified Parkinson Disease Rating Scale (UPDRS) score...

  • Rapid Response Innovation Awards, 2012
    Reversing Pre-existing Pathologies of Dopamine Neurons in an Alpha-synuclein Model

    Objective/Rationale:             
    Alpha-synuclein has been identified to play the central role in Parkinson’s disease. Genome-wide association studies confirm alpha-synuclein as a risk factor for...

  • Research Grant, 2013
    Dynamics of Alpha-synuclein Aggregation in Dopamine Neuron Degeneration and Recovery

    Promising Outcomes of Original Grant:
    Alpha-synuclein is the central player for Parkinson’s disease. Therapies to decrease levels of alpha-synuclein are promising in curing PD. However, it is unknown...

  • Rapid Response Innovation Awards, 2013
    DNA Methylation as a Biomarker for Parkinson’s Disease

    Objective/Rationale:             
    We will test the hypothesis that whole blood DNA methylation in Parkinson’s disease (PD) will be altered at specific sites compared to either healthy controls or to...

  • Rapid Response Innovation Awards, 2013
    Feeding with Clostridium Leptum for Restoring the Integrity of the Striatal Dopaminergic System in a Pre-clinical Model of Parkinson’s Disease

    Objective/Rationale:             
    Inflammation contributes to the pathogenic process of Parkinson’s disease (PD). Increased numbers of anti-inflammatory regulatory T cells (Tregs) has been associated...

  • Synuclein Therapeutic Acceleration Program, 2013
    Quinpramine for Parkinson’s Disease

    Objective/Rationale:             
    A part of Parkinson’s disease progression involves abnormal aggregation of normal brain proteins into knots of insoluble irritant material. The protein involved in...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.